oxybutynin and ADDH studies

oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.

Research Excerpts

Excerpt	Relevance	Reference
" Desmopressin in combination with a fixed dose anticholinergic has been shown to be useful in individuals who fail desmopressin monotherapy, but still fails to achieve success rates greater than 60%."	5.43	Evaluating use of higher dose oxybutynin in combination with desmopressin for refractory nocturnal enuresis. ( Berkenwald, A; Ellsworth, P; Pires, J, 2016)
" Combination therapy with desmopressin and oxybutynin is a feasible, safe and effective treatment for nocturnal enuresis in these children."	5.12	Treatment of nocturnal enuresis in children with attention deficit hyperactivity disorder. ( Abu-Arafeh, W; Chertin, B; Farkas, A; Koulikov, D; Mor, Y; Shenfeld, OZ, 2007)
" Desmopressin in combination with a fixed dose anticholinergic has been shown to be useful in individuals who fail desmopressin monotherapy, but still fails to achieve success rates greater than 60%."	1.43	Evaluating use of higher dose oxybutynin in combination with desmopressin for refractory nocturnal enuresis. ( Berkenwald, A; Ellsworth, P; Pires, J, 2016)

Research

Studies (8)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Efficacy Defined as Change From Baseline on Investigator and Parental/Self-report Based Rating Scales and Questionnaires

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (12.50)	29.6817
2010's	6 (75.00)	24.3611
2020's	1 (12.50)	2.80

Authors	Studies
Berkenwald, A	1
Pires, J	1
Ellsworth, P	1
Chertin, B	1
Koulikov, D	1
Abu-Arafeh, W	1
Mor, Y	1
Shenfeld, OZ	1
Farkas, A	1
Larkin, HD	1
Findling, RL	1
Dinh, S	1
Faraone, SV	1
Hammerness, PG	1
Wilens, TE	1
Reimherr, FW	1
Marchant, BK	1
Olsen, JL	1
Wender, PH	1
Robison, RJ	1
Keating, GM	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy and Safety/Tolerability of Methylphenidate Transdermal System (MTS) for Before-School Dysfunction in Children With Attention Deficit Hyperactivity Disorder (ADHD)[NCT00586157]	Phase 4	36 participants (Actual)	Interventional	2006-09-30	Completed
Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD[NCT00506285]	Phase 3	92 participants (Actual)	Interventional	2007-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The questionnaire includes two a sections, a clinician rated 20-item scale and a 14-item self-report section completed collaboratively by child and parent/guardian.~Units on the clinician rated scale range from 0-3 on a scale of severity, with 0 being the least severe item score and 3 being the most severe. Units on the self-report section ranged from 0-2 on a scale of severity, with 0 being the least severe item score and 2 being the most severe. The possible range of scores for the questionnaire is 88" (NCT00586157)
Timeframe: Baseline and 4 weeks

Efficacy Defined as Change From Baseline on the Investigator Rated DSM-IV Based ADHD Rating Scale, During the AM.

Intervention	Units on a scale (Mean)
MTS (Drug A)	12.76
Placebo	31.37

Units on a scale range from 0-3 on a scale of severity, with 0 being the least severe item score and 3 being the most severe. The possible range of scores for the scale is 0 (least severe) to 54 (most severe). (NCT00586157)
Timeframe: Baseline and 4 weeks

Efficacy Defined as Change From Baseline on the Investigator Rated DSM-IV Based ADHD Rating Scale, Over the Course of the Day.

Intervention	Units on a scale (Mean)
MTS (Drug A)	10.03
Placebo	23.22

Conners' Adult ADHD Rating Scales (CAARS)

Intervention	Units on a scale (Mean)
MTS (Drug A)	14.76
Placebo	28.33

Measures the DSM based ADHD criteria of Inattention and Hyperactivity/Impulsivity. There are 30 items scored 0-3 for a minimum score of 0 (no symptoms) and a maximum score of 90 worst possible symptoms. (NCT00506285)
Timeframe: Double-blind endpoints for MTS and placebo arms

Wender Reimherr Adult Attention Deficit Disorder Scale

Intervention	units on a scale (Mean)
Scores in MTS Arm	30.8
Scores in Placebo Arm	49.5

This scale measures the 7 domains of the Utah Criteria for Adult ADHD. Total scores run from 0 to 28. Normative samples average below 5. The worst possible score is 28. (NCT00506285)
Timeframe: Double-blind endpoints during MTS and placebo arms

Article	Year
Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS). CNS drugs, 2014, Volume: 28, Issue:3 Topics: Administration, Cutaneous; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervou	2014
Drugs for ADHD. The Medical letter on drugs and therapeutics, 2015, Mar-16, Volume: 57, Issue:1464 Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-A	2015

Article	Year
Treatment of nocturnal enuresis in children with attention deficit hyperactivity disorder. The Journal of urology, 2007, Volume: 178, Issue:4 Pt 2 Topics: Antidepressive Agents, Tricyclic; Antidiuretic Agents; Attention Deficit Disorder with Hyperactivity	2007
Reliability and Validity of the Before-School Functioning Scale in Children With ADHD. Journal of attention disorders, 2018, Volume: 22, Issue:11 Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Behavior Rating Scale; Chi	2018
Oppositional defiant disorder in adults with ADHD. Journal of attention disorders, 2013, Volume: 17, Issue:2 Topics: Adult; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperact	2013
Methylphenidate transdermal system in attention-deficit hyperactivity disorder in adolescents: profile report. Drugs in R&D, 2012, Sep-01, Volume: 12, Issue:3 Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Humans; Methylphenid	2012

Article	Year
Evaluating use of higher dose oxybutynin in combination with desmopressin for refractory nocturnal enuresis. Journal of pediatric urology, 2016, Volume: 12, Issue:4 Topics: Adolescent; Antidiuretic Agents; Attention Deficit Disorder with Hyperactivity; Child; Deamino Argin	2016
First Amphetamine Transdermal Patch Approved for ADHD. JAMA, 2022, 05-03, Volume: 327, Issue:17 Topics: Administration, Cutaneous; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervo	2022

oxybutynin and ADDH